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Abstract
Introduction Intraventricular hemorrhage (IVH) affects
15–20 % of babies born before 32 weeks of pregnancy. A
lot of risk factors of developing IVH are known. The making
appropriate recommendations for dealing with infant born less
than 32 weeks of gestation aimed at reducing the incidence of
IVH is still needed. The study aim was to determine the inci-
dence and analyze risk factors of IVH stage 3 and 4 in infants
born before 32+0 weeks of pregnancy.
Methods The retrospective analysis of 267 preterm babies (24
to 32 weeks of gestation) hospitalized in 2011–2013 at
Department of Neonatology, Poznan University of Medical
Sciences was performed. The diagnosis of IVH was con-
firmed by ultrasound scans according to Papille criteria.
Stage 3 and 4 of IVH was confirmed in 14 (25 %) newborns
from 23 to 24 weeks of gestation; 21 (37.5 %) from 25 to
26 weeks of gestation; 11 (19.6 %) from 27 to 28 weeks of
gestation; 9 (16.1 %) from 29 to 30 weeks of gestation; and 1
(1.8 %) from 31 to 32 weeks of gestation.
Result The incidence of IVH stage 3 and 4 was higher in
children: with less use of AST (OR 1.27; 0.62–2.61), born
out of third-level hospitals (OR 2.25; 1.23–4.08), born with
asphyxia (OR 3.46; 1.8–6.64), with acidosis treated with
NaHCO3 (OR 6.67; 3.78–11.75), those who in the first days
of life were treated for hypotension (OR 9.92; 5.12–19.21).
Conclusion No or uncompleted antenatal steroid therapy in-
creased probability for development of severe intraventricular
hemorrhage. Antenatal steroids therapy should be promoted
among women at risk of a premature delivery. Hypotension
therapy with catecholamines and acidosis with sodium hydro-
gen carbonate should be carefully considered. The use of ap-
propriate prophylaxis of perinatal (antenatal steroids therapy
women at risk of preterm birth, limiting the indications for the
use of catecholamines for hypotension treatment and sodium
hydrogen carbonate for acidosis therapy, limitation of preterm
deliveries outside tertiary referral centeres) significantly re-
duces the incidence of intraventricular hemorrhage stage 3
and 4. The significance of intraventricular hemorrhage creates
a need to carry out periodical analysis, at regional level,
concerning its incidence, causes and effects to improve local
treatment outcomes by identifying further courses of action.
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Introduction
Intraventricular hemorrhage (IVH), characterized as bleeding
due to rupture of blood vessels within the germinal matrix
tissue of the developing brain into the ventricular system and
the incidence for IVH grades I–IV, is around 27 % in neonates
weighing less than 1500 g [1]. IVH ranges in severity from
grade I to the most severe grade IV. About 90 % cases of
intraventricular hemorrhage occur within the first 3 days of
the newborn’s life and in 20–40 % of IVH cases become more
extended, during first week of life. In the majority of cases
involving mild bleeding (classified as grade 1 and grade 2), no
clinical effects are observed, usually resolve themselves and
cause no long-term problems. Approximately in 60 % of pre-
mature infants with grade III and IV of IVH incur cognitive
disabilities such as cerebral palsy and mental retardation [2].
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Two hundred sixty-seven premature infants (delivery before
32+0 weeks of gestation) admitted to the Neonatal Intensive
Care Unit at the Department of Neonatology, Poznań
University of Medical Sciences between 2011 and 2013 were
recruited into study.
The study will not include neonates born after 32+0 weeks
of pregnancy, as well as those born frommultiple pregnancies,
from pregnancies complicated by death of one of the fetuses,
chromosomal abnormalities or TORCH (toxoplasmosis, oth-
er, rubella, cytomegalovirus, herpes).
Demographics of this population are described in Table 1.
Diagnosis of intraventricular bleeding
Intraventricular hemorrhage was diagnosed with the use of a
cranial ultrasonographic scan. According to the guidelines of
the American Academy of Neurology (AAN), a routine cra-
nial ultrasonographic scans were performed on 3rd, 7th day of
life, and once more just before discharging from hospital. The
classification of intraventricular bleeding was based on the
Papille IVH classification [3]. In study group diagnosed 110
patients with IVH stage 1; 101 patients with IVH stage 2; 49
patients with stage 3; and 7 patients with stage 4.
Risk factors
We explored the relationship between the occurrence of IVH
and the following prenatal and perinatal variables: gender,
gestational age (GA; weeks), birth weight (BW, grams); ante-
natal steroids therapy (AST, betamethasone 12 mg intramus-
cularly every 24 h for two doses); small for gestational age
(SGA, defined as birth weight under 3rd percentile); type of
delivery (vaginal birth vs. cesarean section); delivery outside
third-level hospitals, birth asphyxia (defined as APGAR score
less than 6 at 10 min and ph<7.0 or blood base excess (BE)<
−15 mmol/l in cord blood); intrauterine infection (defined as
positive culture in sterile originally accompanied by clinical
symptoms); therapy in first 7 days of life with crystalloids
(bolus 10–15 ml/kg) and/or catecholamines of hypotension
(defined as mean blood pressure below value corresponding
to neonate’s gestational age), treatment of the acidosis with
NaHCO3 (when blood pH was below 7.2 and/or BE less than
−10 mmol/l); blood coagulation disorders (defined as
prolonged the prothrombin time (PT) below 65 % and/or in-
creased International Normal Ratio (INR) more than 1.5 and/
or prolonged activated partial thromboplastin time (APTT)
more than 45 s; thrombocytopenia (defined as platelet count
less than 100,000 per microliter of blood) in neonate on de-
veloping IVH.
Statistical analysis
Chi-square test without or with Yates correction were applied
for comparisons of dichotomous variables, where appropriate.
The odds ratio (OR) and 95 % confidence intervals (95 % CI)
were calculated. Unconditional logistic regression analysis
was used to adjust for the effect of confounders such as gen-
der, GA, BW; AST, SGA, outborn patients, birth asphyxia,
intrauterine infection; hypotension, acidosis, blood
Table 1 Characteristic of study population
Group without IVH
and with IVH I and II
stage (N= 211; 79 %)
Group with IVH
stage III and IV
(N= 56; 21 %)
p
Gender 0.853a
Male 116 (55 %) 28 (50 %)




23–24 24 (11.4 %) 14 (25 %)
25–26 65 (30.8 %) 21 (37.5 %)
27–28 54 (25.6 %) 11 (19.6 %)
29–30 45 (21.3 %) 9 (16.1 %)
31 23 (10.9 %) 1 (1.8 %)
Birth weight (gram) 0.464a
<750 38 (18 %) 14 (25 %)
750–1000 70 (33.2 %) 21 (37.5 %)
1000–1500 71 (33.6 %) 15 (26.8 %)
>1500 32 (15.2 %) 6 (10.7 %)
SGA 0.747b
Yes 7 (3.3 %) 2 (3.6 %)
No 204 (96.7 %) 54 (96.4 %)
AST 0.014a
Yes 167 (79.1 %) 35 (62.5 %)
No or
uncompleted
44 (20.9 %) 21 (37.5 %)
Mode of delivery 0.277a
Vaginal 86 (40.8 %) 28 (50 %)
Cesarean section 125 (59.2 %) 28 (50 %)
Third level hospitals 0.005a
Inborn 181 (85.8 %) 42 (75 %)
Outborn 30 (14.2 %) 14 (25 %)
Asphyxia 0.052a
Yes 29 (13.7 %) 13 (23.2 %)
No 162 (86.3 %) 43 (76.8 %)
Intrauterine infection 0.880a
Yes 94 (44.5 %) 26 (46.4 %)
No 117 (55.5 %) 30 (53.6 %)
Hypotension therapy 0.002a
Yes 131 (62.1 %) 47 (83.9 %)
No 80 (37.9 %) 9 (16.1 %)
Acidosis therapy 0.003a
Yes 122 (57.8 %) 45 (80.4 %)






Yes 4 (1.9 %) 2 (3.6 %)
No 207 (98.1 %) 54 (96.4 %)
a Chi-square test
b Chi-square test with Yate’s correction
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coagulation disorders, thrombocytopenia was used to make
adjustment of parameters. A P value below 0.05 was judged
to be statistically significant.
Aforementioned statistical calculations were performed
using CytelStudio version 10.0, created January 16, 2013
(CytelStudio Software Corporation, Cambridge, USA), and
Statistica version 10, 2011 (Stat Soft, Inc., Tulsa, USA).
Results
The incidence of IVH stage 3 and 4 was comparable in female
(n=28; 50 %) and male (n=28; 50 %) neonates with no sig-
nificance. The risk of IVH stage 3 and 4 was the greater the
lower the gestational age and was significantly higher in chil-
dren born 23–24 weeks of gestation (OR 18.39; 6.4–54.98),
25–26 weeks of gestation (OR 9.63; 3.98–25.48), 27–
28 weeks of gestation (OR 5.52; 2.1–15.53) and 29–31 weeks
of gestation (OR 3.82; 1.31–11.51) comparing to children
born after 32 weeks of gestation. The incidence of IVH stage
3 and 4 was higher in children: with less use of AST
(p=0.014; OR 1.27; 0.62–2.61), born out of third-level hos-
pitals (p=0.007; OR 2.25; 1.23–4.08), born with asphyxia
(p<0.0001; OR 3.46; 1.8–6.64), with acidosis treated with
NaHCO3 (p<0.0001; OR 6.67; 3.78–11.75), those who in
the first days of life were treated for hypotension
(p<0.0001; OR 9.92; 5.12–19.21). There was no significance
increase incidence of IVH stage 3 and 4 in neonates sponta-
neous delivered vs by cesarean section, children with SGAvs
AGA, children with intrauterine infection and neonates with
blood coagulation disorders and/or thrombocytopenia after
birth.
Multivariate analysis revealed that the more risk factors
present the greater chance incidence of IVH 3 and 4 stage
and in children born before 32 weeks of gestation and without
AST (p=0.0387; OR 1.27; 0.62–2.61), and born with asphyx-
ia (p = 0.0029; OR 1.52; 0.67–3.46), and hypotension
(p < 0.0001; OR 4.35; 1.81–10.47) and with acidosis
(p<0.0001; OR 5.17; 2.22–12.03).
Seven of 267 (2.6 %) patient died, including 2 of 38 (5.3 %)
newborns from 23 to 24weeks of gestation; 2 of 86 (2.3%) from
25 to 26 weeks of gestation; 1 of 65 (1.5%) from 27 to 28 weeks
of gestation; 2 of 54 (3.7%) from29 to 30weeks of gestation and
none from31weeks of gestation. Five of 56 (8.9%) patientswith
stage III and IV of IVH died, of which none was born respec-
tively in 23–24; 2 (9.5%) in 25–26; 1 (9%) in 27–28; 2 (22.2%)
in 29–30 and none in 31 weeks of gestation.
Discussion
The role of hypotension and its involvement in the pathogen-
esis of complications in preterm infants is not clear. Research
into various factors involved in the etiopathogenesis of IVH
list hypotension among the risk factors for it. Different results
were presented by Batton et al. [4] who did not find significant
differences in the psychomotor development between new-
born infants who were treated for hypotension and those
who were not. Similarly, Alderliesten et al. [5] did not deter-
mine an association between hypotension and the develop-
ment of adverse neurological outcomes. Therefore, a question
may be asked whether hypotension among newborn infants
should be treated or not. Current guidelines in many countries
(e.g., USA, the UK, Poland) are similar. The first line of ther-
apy is crystalloid fluid infusion to eliminate hypovolemia as
the potential reason for hypotension. The next line of therapy
is catecholamines, introduced in the following order: dopa-
mine at 10–20 μg/kg/min, optionally combined with dobuta-
mine at 20–40 μg/kg/min. If there is no therapeutic effect after
dopamine and dobutamine have been administered, adrenalin
or noradrenalin is recommended, at respective doses of 0.05
and 0.1–1 μg/kg/min. The next step is the use of corticoste-
roids: 1–2 mg of hydrocortisone per kg of body weight given
every 6–8 h [6]. Unfortunately, as demonstrated in our study,
catecholamine therapy increased the risk of development of
IVH (grade 3 and 4) among infants born before week 32 of
gestational age. The results of other research are comparable.
In their study carried out on a group of 153 neonates, Rong
et al. [7] found catecholamine therapy to be a risk factor for
IVH. AnAmerican study of infants with VLBW confirmed an
increased risk of IVH development and higher mortality rates
among the neonates treated for hypotension. Moreover, in this
group, a higher risk of later complications, including hearing
impairment or cerebral palsy, was observed, compared to in-
fants without hypotension or hypotensive untreated infants.
This might suggest that refraining from treatment of hypoten-
sion is safer for premature infants than catecholamine therapy.
Alternative forms of treatment should also be considered.
Ibrahim et al. [8] found that hydrocortisone used to treat hy-
potension had similar effectiveness to dopamine. Moreover,
when compared to placebo, hydrocortisone does not increase
the risk of IVH nor infant mortality rates. The appropriate
criteria of initiating catecholamine treatment are not
established. One of the most popular criteria is a fall of blood
pressure 5mmHG less than correct level and the presence of at
least two indicators of hypoperfusion, such as average blood
pressure lowered by 3 mmHG, lactate >4 mmol/l, capillary
refill time >4 s [9]. In their other research, Batton et al. initi-
ated hypotension treatment on 203 neonates born between
23rd and 26th week of pregnancy, basing on 15 different def-
initions of hypotension. In all treated groups, higher risk of
appearing IVH and lower survival rate were observed.
Independently from the moment of administration, catechol-
amines caused higher risk of appearance of the aforemen-
tioned complications [10]. Currently in preterm infants should
be taken into consideration the permissive hypotension. A
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numerical blood pressure value lower than gestational age
should not be used as the only indicator for treating early
period hypotension in VLBW. Hypotension treatment should
be administered based on clinical condition of patients [11].
Another risk factor for grade 3 and 4 IVH, confirmed also
in our study, is a lack of AST in pregnant women at risk of a
premature delivery. The main objective of the use of steroid
therapy is to prevent respiratory distress syndrome (RDS) by
stimulatingmaturity of fetal respiratory system. ASTstimulate
development of type 1 and type 2 pneumocytes. Induction of
type 2 pneumocytes increases surfactant production by induc-
ing production of surfactant proteins and enzymes necessary
for phospholipid synthesis. Moreover, ASTaccelerate absorp-
tion of lung fluid after the birth due to induce of pulmonary
beta-receptors, fetal lung antioxidant enzymes, and upregula-
tion of gene expression for the epithelial Na+ channel [12]. A
Cochrane review showed that AST reduced the risk of neona-
tal death by 31 %, RDS by 44 %, and IVH by 46 % [13]. A
2016 meta-analysis of randomized trials of antenatal cortico-
steroid therapy before 24 weeks of gestation demonstrated a
reduction in perinatal mortality at 23 weeks of gestation (OR
0.45, 95%CI 0.33–0.60), and a possible reduction at 22weeks
(OR 0.66, 95 % CI 0.40–1.07). No statistical reductions were
observed for respiratory distress syndrome, severe intraven-
tricular hemorrhage, or necrotizing enterocolitis at <24 weeks
[14]. Royal College of Obstetricians and Gynecologists rec-
ommends AST to women between 24+0 and 34+6 weeks of
gestation who are at risk of preterm birth. AST should be
considered for women between 23+0 and 23+6 weeks of
gestation who are at risk of preterm birth [15]. According to
current guidelines of the Polish Gynecological Society, AST is
recommended between weeks 24 and 36 of pregnancy in
pregnant women at risk of a preterm delivery. The preferred
drug is betamethasone, due to a larger number of available
studies that confirm its effectiveness [16]. In the group studied
by us, a lack of AST caused a twofold increase in the risk of
IVH. To summarize the conclusions resulting from a variety
of studies, the use of ASTadministered when indications exist
is very important in reducing the risk of preterm-associated
morbidities.
In our study group, we found that asphyxia represents one of
the factors that increase the risk of severe IVH. Asphyxia is
related to abnormal gas exchange which results in oxygen deficit
and hypercapnea. In a study by Liu et al. [17] on 1122 infants
born before week 37 of gestational age, asphyxia is mentioned as
one of major risk factors for IVH. Severe asphyxia, defined as
Apgar score of ≤3 at 1 and 5 min, is also listed as an IVH risk
factor in infants with birth weight <1500 g (Adegoke et al.) [18].
These results from coagulation cascade disruptions caused by
asphyxia, and from impaired aggregation of platelets. Even
though some studies indicate that asphyxia per se does not cause
neurodevelopmental impairment, hypoxia—which is its conse-
quence—may result in serious morbidities. Even a small change
in oxygen supply to the brain increases the risk of hemorrhage in
the central nervous system. Even with appropriate saturation,
cerebral regional oxygen saturationmay be impaired, which con-
siderably increased the risk of IVH in the group of preterm in-
fants analyzed by Baik et al. [19]. In view of the above, preven-
tion against and early diagnosis of asphyxia turns out to be im-
portant. Again, one should remember about AST that prevents
RDS one of major causes of asphyxia.
In our study, the cut-off point for acidosis was set at pH below
7.2 and/or BE less than −10. For therapy sodium hydrogen car-
bonate (NaHCO3) was used. As shown in our analysis, acidosis
increased the risk of severe IVH (grade 3 and 4) in preterm
neonates born before 32 weeks. With regard to the intrinsic ad-
verse effect of acidosis on the development of IVH,many studies
take a consistent standpoint. A study by Randolph et al. [20] on a
group of 3979 patients with VLBW, focusing on the effects of
acidosis in preterm infants, indicated an increased risk of severe
IVH as well as higher mortality rates and higher incidence rates
of neurodevelopmental impairment. The study by Rong et al. [7]
also listed acidosis among risk factors that have a disruptive
impact on hemodynamic processes and thus play a role in the
pathogenesis of IVH. In a study carried out by Adegoke et al.
[18] on the group of 87 preterm infants with birth weight
<1500 g the association of acidosis and IVHwas also confirmed.
Negative effects of acidosis are a result of its impact on hemo-
stasis. Excessive acidity inhibits platelet aggregation, thus pro-
moting hemorrhage. There is still discussion concerning therapy
for acidosis. Administration of NaHCO3 is a commonly used
method but its impact on the development of IVH is not obvious,
as the results of studies are ambivalent. Xu et al. [21] investigated
a group of 59 preterm neonates and concluded that the infusion
of NaHCO3 directly changed the volume of blood in circulation
and, indirectly, had an impact on the hemodynamics of cerebral
circulation and, consequently, increased the risk of IVH. In a
retrospective analysis of 3806 cases of children born <33 weeks
of pregnancy Synnes et al. [22] demonstrated an association of
the therapeutic use of NaHCO3 with IVH occurrence. They em-
phasize in their study that it is one of the modifiable risk factors
and finding a better therapy might cause a decrease in that risk.
Other sources, on the other hand, do not confirm the adverse
impact of NaHCO3. A study by Beveridge and Wilkinson [23]
demonstrated that there were no differences between sodium
hydrogen carbonate infusion versus dextrose with regard to
IVH, encephalopathy, and neonatal seizures. Even though no risk
increase related to the use of NaHCO3 was detected, the authors
noted that there was insufficient research evidence to determine
whether the therapy actually reduced mortality in infants. While
it is important to effectively prevent and treat acidosis, there is
insufficient evidence to justify an intervention using NaHCO3.
Another IVH risk factor which was detected in our study was
the delivery that took place at a facility other than a tertiary
referral center. Tertiary referral centers are public academic and
research hospitals. They carry out academic research, have more
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specialized equipment and highly trained staff. These are the
likely reasons why delivery at a hospital other than a tertiary
referral center was related to a higher risk of IVH. Another factor
contributing to an increased risk might have been the transport of
premature neonates from lower-level referral centers to our hos-
pital. As shown in an American study comprising 67,596 infants
with birth weight <1500 g born between 1997 and 2004, moving
the infant from one hospital to another increased both the fre-
quency and the severity of IVH. It is not completely clear what
contributed to the increase in risk, but the aspects considered
were vigorous manipulations, kinking or obstruction of the en-
dotracheal tube, self extubation, or iatrogenic trauma during neo-
natal transport [24]. Similarly, Chinese research also confirmed
the adverse effect of neonatal transport on the development of
IVH [7]. In addition to the aspects listed above, variations in
ambient temperature were also considered to be a likely cause.
With theminimization of potential risk inmind, women at risk of
premature delivery and perinatal complications should, whenev-
er possible, give birth at facilities with higher reference status.
Conclusions
No or uncompleted antenatal steroid therapy increased probabil-
ity for development of severe intraventricular hemorrhage.
Antenatal steroids therapy should be promoted among women
at risk of a premature delivery. Hypotension therapy with cate-
cholamines and acidosis with sodiumhydrogen carbonate should
be carefully considered. The use of appropriate prophylaxis of
perinatal (antenatal steroids therapy women at risk of preterm
birth, limiting the indications for the use of catecholamines for
hypotension treatment and sodium hydrogen carbonate for aci-
dosis therapy, limitation of preterm deliveries outside tertiary
referral centeres) significantly reduces the incidence of intraven-
tricular hemorrhage stage 3 and 4. The significance of intraven-
tricular hemorrhage creates a need to carry out periodical analy-
sis, at regional level, concerning its incidence, causes and effects
to improve local treatment outcomes by identifying further
courses of action.
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